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Unusual Presentation and Rare 




Graves’-Basedow’s disease (GD) is a well-defined hyperthyroid disorder caused 
by circulating antibodies that results the overproduction of thyroid hormones. All 
but a few children present with some degree of thyroid gland enlargement and most 
have two or more signs of excessive thyroid activity, such as tremor, irritability/
nervousness, tachycardia etc. Fully developed clinical picture is easy to recognize 
while often the onset is insidious. Thyroid hormones affect many body systems, so 
signs and symptoms of Graves’ disease can be wide ranging. A survey on PubMed 
literature was conducted to gather all published pediatric Graves-Basedow’s cases 
with unusual presentation at the time of diagnosis. We found all together 70 
manuscripts with relevant information from 1978 to 2020 but mainly adult cases. 
One third of them were found to meet the criteria we focused on and were included 
in this paper, though in some situation the unusual findings do not consist part of 
hyperthyroidism, the rare manifestation is only a coexistence, or the serious disease 
even precedes the GD. Dermatopathy, hepatic dysfunction, impaired fluid balance, 
concomitant disorders in thyrotoxicosis, tricky laboratory findings, a phenomenon 
of metamorphic thyroid autoimmunity, peculiarities of thyroid dysfunction in 
children with Down syndrome, apparent associations, and reconstitution GD are 
highlighted in this chapter. Awareness about the relation of these remote findings 
to GD, or frequent coexistence with GD is important for early diagnosis. Finally, a 
reasonable suspicion for Graves’ disease may ultimately help to prevent unnecessary 
investigations and treatment.
Keywords: hyperthyroidism, thyrotoxicosis, thyroid autoimmunity, antibodies,  
rare disorder, Hashimoto thyroiditis, Turner syndrome, Down syndrome, 
reconstitution GD, children
1. Introduction
In pediatric age group the Grave’s-Basedow disease (GD) is by far the most 
common cause of hyperthyroidism, accounting for greater than 95% of cases. The 
underlying process is an autoimmune reaction with cell proliferation and excess 
function (overproduction of thyroid hormone) caused by anti-thyrotropin recep-
tor antibody (TRAb). When using term thyrotoxicosis, it depicts the clinical and 
biochemical manifestations of excess thyroid hormones. The annual incidence 
of thyrotoxicosis was less than 1 per 100,000 children <15 years of age in the last 
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century and rised slowly above 1.5 per 100,000 by 2012 with the pubertal domi-
nance up to 80%. In spite of the GD is a rare disorder in children, physicians should 
consider Graves’ disease in any child with clinical manifestations of hyperthyroid-
ism, regardless of the age.
All but a few GD children present with some degree of thyroid gland enlarge-
ment and most have two or more signs of excessive thyroid activity. The clinical 
manifestations of hyperthyroidism during fetal life are tachycardia, cardiac 
arrhythmia, intrauterine growth retardation and may be associated with nonim-
mune fetal hydrops, craniosynostosis. Features of this condition in the neonate 
include irritability, tachycardia, hypertension, cardiac failure and arrhythmias, 
diarrhea, poor weight gain, vomiting, jaundice, hepatosplenomegaly, ophthal-
mopathy, craniosynostosis and thyroid enlargement. In childhood hyperkinesis, 
tachycardia, tremor, frequent stools, nervousness are the signs of hyperthyroidism 
but in young children these are less characteristic, often unrecognized. In school-
age hyperthyroidism neuropsychiatric symptoms such as hyperactivity and poor 
school performance are common features. Adolescents usually present with classic 
signs including weight loss despite of good appetite, diarrhea, nervousness, and 
heat intolerance. Fully developed clinical picture is easy to recognize while often 
the onset is insidious. Thyroid hormones affect many body systems, so signs and 
symptoms of Graves’ disease can be wide ranging.
This chapter is aimed to draw attention to less common or less distinctive signs 
and symptoms which can be in relation to GD at the time of diagnosis. A survey was 
conducted on PubMed literature to gather all published pediatric Graves-Basedow’s 
cases with unusual presentation at the time of diagnosis. We found all together 70 
publications with relevant information from 1978 to 2020 but mainly adult cases. 
Half of them (36) were found to meet the criteria we focused on and were included 
in this paper, though in some situation the unusual findings do not consist part of 
hyperthyroidism, the rare manifestation is only a coexistence, or the serious disease 
even precedes the GD. Awareness about the relation of these rare manifestations or 
disorders to GD is essential to avoid wrong diagnosis, unnecessary investigations, or 
fatal outcome due to delay of diagnosis.
2. Unusual signs and symptoms
2.1 Dermopathy and acropachy
Thyroid dermopathy (TD), also called pretibial myxedema and thyroid 
acropachy (TA) together with Graves’ orbitopathy (GO) are extrathyroidal 
manifestations of GD. Graves’ ophthalmopathy in children not as common as in 
adults and less severe than in later age. Dermatological symptoms are rare and 
in general develop sequentially: Dermopathy is usually present if the patient is 
also affected with GO. The very rare acropachy occurs only in patients who also 
have dermopathy [1]. Or in other words, acropachy is an indicator of severity of 
ophthalmopathy and dermopathy. All have an autoimmune origin, the immune 
reaction is targeted to TSH receptor and, likely, the IGF-I receptor. Typical 
presentation of dermopathy is nonpitting edema or plaque-like lesions on the 
pretibial region, while thyroid acropachy presents as digital clubbing, swelling of 
digits and toes, and periosteal reaction of extremity bones. Awareness about the 
relation of TA to GD is important as clubbing usually is not a patient complaint 
and is noted only by clinical observers. Recently Kraus CN and al. reported a 
case of acropachy in a child as well as reviewed the literature of pediatric thyroid 
dermopathy [2].
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2.2 Cholestasis
Hepatic dysfunction is commonly observed in patients with thyroid disease, it 
can be categorized mainly into group with either hepatocellular damage (transami-
nases elevations), or intrahepatic cholestasis (bilirubin elevation). In newborn, the 
hypothyroidism is the most typical thyroid disorder associated with cholestasis. 
Jaundice due to intrahepatic cholestasis may be a salient symptom in GD patients, 
and very occasionally, it is the presenting manifestation of thyrotoxicosis. The 
mechanism of liver injury in pure hyperthyroid states is not well understood, and 
no correlation was documented between abnormal liver biochemical tests and 
thyroid hormone levels. A contributing factor appears to be relative hypoxia in the 
perivenular regions, due to an increase in hepatic oxygen demand without an appro-
priate increase in hepatic blood flow [3], the other might be the thyroid hormones 
themselves with a direct toxic effect on hepatic tissue in hypermetabolic state [4]. 
If other possible causes of cholestasis are excluded, recovery occurs parallelly with 
restoration of euthyroidism. In the absence of another evidence of liver disease, 
and when jaundice is purely due to the hyperthyroidism, thionamide drugs may be 
used with monitoring of serum bilirubin and liver function tests [5]. Newborns and 
adolescent patient were reported with jaundice/hyperbilirubinemia as manifesta-
tion of GD hyperthyroidism [6–8].
2.3 Polydipsia, nocturnal enuresis
Disturbance of water homeostasis can lead to polyuria-polydipsia syndrome, 
which is a diagnostic challenge. Polydipsia is a nonspecific symptom in various 
diseases, often accompanied by polyuria. Increased thirst and/or nocturnal enuresis 
can be the main complains, and a careful case history usually reveals the primary 
reason (disturbed input or output). Polydipsia has been described as a presenting 
symptom of hyperthyroidism in adults. A few years back a serendipitous identifica-
tion of GD in identical twin girls with polydipsia was published [9]. Though etiol-
ogy of nocturnal enuresis is not fully understood, evidence is growing that enuresis 
may have a central origin: bedwetting children have lower brainstem reflex control 
(impaired prepulse inhibition) than normal controls [10]. A case of a 9-year-old 
boy has been reported by the same team who suffered from hyperthyroidism and a 
new appearance of enuresis. Bedwetting ceased and prepulse inhibition – measured 
as a parameter of central control – increased during on course of anti-thyroid 
therapy [11]. In our praxis we experienced two GD cases where nighttime inconti-
nence was the presenting feature of recurrent hyperthyroidism.
3. Rare concomitant disorders
3.1 Thyrotoxic periodic paralysis
Thyrotoxic periodic paralysis (TPP) is a rare disease of the muscles secondary to 
hyperthyroidism presenting sudden attacks of short-term muscle weakness, stiff-
ness, or paralysis. The underlying mechanism is malfunctions in the ion channels 
in skeletal muscle cell membranes: An increased influx of potassium into skeletal 
muscle cells leads to profound hypokalemia and paralysis. Hypokalemia in thy-
rotoxic hypokalemic periodic paralysis (THPP) results from an intracellular shift 
of potassium and not total body depletion. The symptoms may be mild or severe, 
and they may last for minutes or days, involving the whole body or just one or 
both limbs. The severity of the disease does not correlate with the hormone levels, 
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and muscle paralysis simply resolves by achieving the euthyroid state. TPP most 
frequently seen in Asian men and also reported in Hispanic adolescent males [12, 
13]. Fatal outcome of a 10-years-old girl with delayed diagnosis of hyperthyroid-
ism should draw attention to the awareness about this rare but potentially lethal 
disorder [14].
3.2 Encephalopathy
Presenting feature of encephalopathy in GD and Hashimoto’s thyroiditis 
would be similar (seizures, stroke-like episodes, cognitive decline, neuropsy-
chiatric symptoms etc.) but characteristics of thyroid derangement is reversed. 
Thyroid function is not an issue in Hashimoto’s encephalopathy which is renamed 
now as ‘steroid responsive encephalopathy associated with autoimmune thyroid-
itis (SREAT)’, while brain dysfunction is associated to hyperthyroid state in GD. 
Hecht T and coworkers reported on a 7-year-old girl with generalized seizures, 
somnolence, fever, and respiratory distress. The increase of sinus tachycardia 
with good hydration, sufficient analgesia, and hyperthermia led to the determi-
nation of thyroid hormones, and therefore finally to the diagnosis of a thyrotoxic 
crisis in Graves’ disease. Symptoms were disappeared by thyrostatic therapy 
[15]. They concluded that thyrotoxic crisis should be considered a differential 
diagnosis in case of resistant unexplained sinus tachycardia, seizures, and 
encephalopathy.
4. TSHR-blocking autoantibody (TBAb)
In Graves-Basedow’s patients TRAb stimulates thyroid hormone synthesis by 
activating the TSH receptor (stimulating TRAb /TSAb/, TSHR agonist). TSHR 
antibodies that lack agonistic activity but are competitive inhibitors of TSH bind-
ing can cause hypothyroidism (blocking TRAb/TBAb/, TSHR antagonist). There 
is a wide variety of TSHR antibody assays employed in the past and nowadays. 
Depending on the underlying method, two types of assays are important for 
determination of circulating autoantibodies: Competition for ligand binding or 
measuring bio-response. A rare history of monozygotic 10-year-old twins was 
published who presented with hyper- and hypothyroidism, respectively [16]. Both 
girls had antibodies against thyrotropin receptors as measured by a radioreceptor 
assay. Analyzing further the sera in a functional bioassay, the TSH receptor anti-
bodies of the hyperthyroid twin displayed stimulatory activity typical of Graves’s 
disease, while the antibodies of the hypothyroid twin acted as pure antagonists at 
the TSH receptor level. This is a proven pediatric case with hypothyroidism due to 
thyroid (or TSH)-blocking antibodies, where the pathogenesis was similar to GD. 
In the following 30 years an extensive work of research groups has led to significant 
improvements that has enabled bioassays to be employed routinely in clinical labo-
ratories: 1, Two human monoclonal antibodies (MAbs) with TSHR agonist activity 
(M22 and K1-18), one human MAb with TSHR antagonist activity (K1-70) and one 
human MAb (5C9) with both TSHR antagonist and TSHR inverse agonist activity 
have been isolated [17]. 2, Currently available highly sensitive and specific assays to 
measure TRAbs use the human TSHR monoclonal antibody (Mab) M22 instead of 
the TSH [18]. Based on a research-use only service offered by RSR Limited, an adult 
case of woman with fluctuating hypo- and hyperthyroidism was published provid-
ing proof that a patient can produce a mixture of blocking and stimulating TSHR 
autoantibodies at the same time [19].
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5. Metamorphic thyroid autoimmunity
Here we overview the phenomenon of metamorphic thyroid autoimmunity 
anticipating, that more investigational studies are needed to reveal the underlying 
mechanism, and larger epidemiological studies are needed to confirm that this find-
ing is not unusual but is rather under-recognized in pediatric population. The term 
metamorphic thyroid autoimmunity was introduced by Ludgate M. and Emerson 
H. commenting cases with a conversion from Hashimoto thyroiditis (HT) to GD or 
vice versa [20–22]. A few years later Wasniewska M et al. aimed to ascertain HT in 
the history of GD children order to assess the relative frequency of this phenom-
enon [23]. Based on retrospective data of a cohort of 109 GB children and adoles-
cents without coexistent chromosome abnormalities they calculated the frequency 
between 3 and 4%. Reporting results they confirmed the existence of a possible 
continuum between HT and GD within the spectrum of autoimmune thyroid 
diseases. In search of switching process from HT to GB in patient with either Turner 
syndrome (TS) or Down syndrome (DS) the same team found that antecedents of 
HT were significantly more common in chromosomopathy group (9/35 = 25.7%) 
compared to age-matched GD patients (4/109 = 3.7%) [24]. Guessing the clue of 
this immunological paradigm it should take into high consideration that attribute 
of HE is a cell-mediated destruction of thyroid tissue with hypo- or euthyroidism 
while GB is a TRAB-mediated gland activation presented in hyperthyroidism. In 
general, thyroid autoimmunity involves loss of tolerance to thyroid proteins in 
genetically susceptible individuals in association with environmental factors, no 
single mechanism explains the altered immune-reaction. Further immunological 
and genetic investigations can add explanatory information to this unusual pendu-
lum swinging thyroid autoimmunity.
6. Peculiarities in Down syndrome
6.1 Asymptomatic vs. cumulative presentation
Thyroid derangement is the most frequently encountered endocrinopathy in 
Down syndrome (DS) affecting almost half of the patients (7 - 66%). Based on 
this fact the life-long monitoring of the thyroid function is recommended for all 
DS patients. Thyroid abnormalities encompass mainly any kind of hypothyroidism 
(congenital, primary, subclinical, or overt hypothyroidism), isolated hyperthyro-
tropinemia, Hashimoto thyroiditis or very rarely GD. Autoimmune thyroid disease 
is uncommon in young children with Down’s syndrome but is common after 8 years 
of age [25]. A Spanish group [26] reported on three DS children with GD: Two 
of them were asymptomatic for thyroid hyperfunction (a 14-year-old girl and an 
8-year-old boy), while the third child (a 12-year-old girl) presented goiter, ner-
vousness, weight loss and tachycardia. In addition to the typical features of hyper-
thyroidism, the patient showed right-side heart failure and elevated transaminases, 
which disappeared with antithyroid treatment. Though annual biochemical screen-
ing for early detection of thyroid hypofunction is reasonable, regular auxological 
and clinical assessment in syndromic patients is also important.
6.2 Metamorphic thyroid autoimmunity
HT and GB are two different disease entities in the spectrum of thyroid autoim-
munity presenting dominantly with hypothyroidism (HT) or with hyperthyroidism 
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(GB). A metamorphosis of both clinical and biochemical phenotype from HT to 
GD or vice versa has been discussed for more than 10 years [22] based on sporadic 
cases. A tapered Italian team conducted several retrospective studies to shed light 
on this phenomenon in pediatric population. In 2015 they published a research 
paper reconstructing the conversion process from HT to GD and the subsequent 
evolution of GD in a series of 12 children (7 girls/5 boys) with DS [27]. All patients 
fulfilled the criteria for diagnosis of HT and GD taking laboratory measurements 
and ultrasonography scan. Time interval between HT diagnosis and GB presenta-
tion ranged from 0.7 to 6.5 years, and Graves’ disease showed a milder clinical and 
biochemical course in this cohort. Summing up they conclude that „1, DS children 
might be incline to manifest over time a phenotypic metamorphosis from HT to GH 
and to subsequently fluctuate from hyperthyroidism to hypothyroidism; 2) in DS 
GD may have a mild biochemical and clinical course” [27].
6.3 Unusual scenario
A DS case with an unusual thyroid constellation were published by Nebesio TD 
and Eugster EA. „ A 10-year-old girl with Down syndrome was diagnosed with 
congenital hypothyroidism in the newborn period due to left thyroid hemiagenesis. 
Unexpectedly, her hypothyroidism resolved at the age of 3 years. After being off 
thyroid hormone replacement for 7 years and having normal thyroid function, she 
developed Graves’ disease with typical signs and symptoms of hyperthyroidism 
including diarrhea, inattention, and hyperactivity” [28]. This case highlights also 
the unpredictable course of thyroid disease which may occur in children with Down 
syndrome.
7. Coincidence in polyendocrinopathy APS3
The autoimmune polyglandular syndromes (APS1-4) encompass a wide clinical 
spectrum of disease with different (monogenic/complex) genetic etiologies and 
heterogeneous presentation. APS2 is defined by presence of primary adrenocortical 
insufficiency with either autoimmune thyroid disease or type 1 diabetes mellitus in 
the same patient. The clinical diagnosis of APS3 requires the presence of an autoim-
mune thyroid disease and an additional autoimmune illness other than Addison’s 
disease; a frequent combination is pernicious anemia, vitiligo, alopecia, myasthenia 
gravis and Sjögren sy. Thyroid disease purports a variety of thyroid disorders. 
Hypothyroidism is more common than Graves’ disease, and GD tends to manifest at 
a younger age. Recently Klenczar K and coworkers reported on a 11-year-old female 
patient, who presented coincidence of T1DM with other autoimmune diseases, such 
as Graves-Basedow’s disease, myasthenia gravis, vitiligo, and IgA deficiency [29]. 
The clinical picture of this case fulfilled the criteria of autoimmune polyglandular 
syndrome type 3.
8. Unexpected coexistence
Stickler syndrome is a rare genetically heterogeneous disorder of the connective 
tissue, caused by abnormal synthesis of type II, XI, or IX collagen. It is character-
ized by a distinctive facial appearance, eye abnormalities, hearing loss and joint 
problems. Ocular involvements are early onset cataract, myopia, abnormal vitre-
ous humor, retinal detachment, and most of the patients exhibit short stature. 
Onesimo R et al. reported on a 5-year-old girl affected by Stickler syndrome who 
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was diagnosed with GD in preclinical state, during health supervision and evalua-
tion by pediatric endocrinologist for short stature [30]. None of her family member 
suffered from autoimmune thyroid disorder and her medical history was negative 
for autoimmune disease. Association between Stickler’s syndrome and GD in this 
case seems to be an incidental coexistence.
9. Reconstitution Graves’ disease
Reviewing the manuscripts on Graves’ disease and rare comorbidity, a new 
issue has been raised. Growing numbers of publication on the association between 
biological treatment for life-threatening and/or medication-refractory disorders, 
and the development of autoimmune hyperthyroidism in adults, call the attention 
to secondary GD [31, 32]. The use of different modality targeting the immune 
system as a curative therapy (e.g. hematopoietic stem cell transplantation /HSCT/, 
antithymocite globulin/ATG/, antiretroviral therapy/ART/etc.), has had a profound 
impact on clinical outcomes. A subset of patients may experience immune restora-
tion disease (IRD)/immune reconstitution inflammatory syndrome (IRIS) affecting 
the thyroid gland in two form, such as Hashimoto thyroiditis or Graves’ hyperthy-
roidism. Although both are more common in children because of early thymic dam-
age, it has received little attention in pediatric literature [33]. Sporadic cases were 
reported on challenging autoimmune processes: Defective T-cell function take place 
during the pathogenesis both of aplastic anemia (AA) and GD. Antithyroid drugs 
used for the management of GD may induce AA and GD may occur following treat-
ment of severe aplastic anemia (SAA). The latter occurred in a 11-year-old girl who 
had been treated with allogenic HSCT at age of 8 years as having severe acquired 
AA [34]. A case of another child was published earlier with chronic relapsing severe 
aplastic anemia and GD [35]. Authors supposed a close relation in manifestation of 
hypertyroidism due to withdrawal of immunosuppressants. In adult patients the 
secondary GD may exhibit a fluctuating course, with alternating phases of hyper- 
and hypothyroidism, due to the coexistence of TRAb with stimulating and blocking 
function [36]. Clinicians need to remain vigilant when initiating immune reconsti-
tution therapy, and a careful management and follow-up for thyroid function after 
these treatments are essential.
10. Discussion
In this chapter we presented a spectrum of unusual clinical findings, signs of 
Graves-Basedow’s disease in childhood, but atypical laboratory results. Less com-
mon and less distinctive features detailed above are well documented in adults, 
which suggests that these are neither age-dependent nor characteristic to pediatric 
GD. Though the mechanism remains uncertain in majority of unusual manifesta-
tions, the recovery that occurs parallelly with restoration of euthyroidism, gives the 
evidence of their relation to GB hyperthyroidism. Metamorphic thyroid autoim-
munity, a phenomenon of conversion from Hashimoto thyroiditis to Graves’ disease 
is also summarized without guessing the clue of this immunological paradigm. 
Existence of a continuum between HT and GD within the spectrum of thyroid 
autoimmunity is confirmed in pediatric population without coexistent chromo-
some abnormalities, also in children with Turner or Down syndrome. Beside this 
peculiar event sequence, GD in DS patient can be insidious by presenting delayed 
clinical symptoms even with multiple organ derangements. In some rare syndromic 
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the occurrence of Graves’ hyperthyroidism. Finally, a very vulnerable population 
with malignancy, immune deficiency syndromes, hemoglobinopathies and other 
disorders attract attention with a possible secondary GB following immune recon-
stitution therapy. Awareness about the relation of these remote findings to GD, or 
frequent coexistence with GD is important for early diagnosis, and a reasonable 
suspicion for Graves’ disease may ultimately help to prevent unnecessary investiga-
tions and treatment.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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